Evan Garrad (@GarradEvan) header
Evan Garrad (@GarradEvan) profile picture

R38 StARR Fellow | IM @UICIMChiefs | Aspiring Hematologist/Oncologist | MRSP @NIH | @SpursOfficial ⚽️

Chicago, IL
Joined July 2021
Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)Photo by Evan Garrad (@GarradEvan)
Celebrating @FrankWeinbergMD’s birthday a little early in clinic today! I think this photo captures a bit of what makes him such an amazing oncologist, mentor, and person!
2
5
334
Incredible cancer breakthrough #ESMO26 w/ new benchmark in melanoma & huge advances for all future personalized tx that could extend to other cancers 🌟 Ph3 Intismeran autogene mRNA vaccine improved RFS by 42% w/ Pembro vs Pembro alone, distant mets reduced by 38%, similar AEs
10
22
1,026
What a wonderful #ASCOQLTY26! From PROs, AI & #SuppCare to health equity, implementation science & patient-centered care! THANK YOU to all @ASCO staff, speakers, presenters & attendees who made this meeting so special! 👏 Congratulation @RyanNipp on a record-breaking 1,000+ attendees! Looking forward to #ASCOQLTY27 w @WhatsUrHari as Chair!
🤖 Made with AI
15
42
1,628
Poster sessions at #ASCOQLTY26 started off 🔥 this morning Highlights: precision oncology workflow to identify actionable mutations, insurance coverage in disaggregated Asian Americans and NHPI, and more! Come back this afternoon to check out posters 📍D1, F2, and Q1!
6
18
570
Congratulations to the 2026 @ASCO Quality Care Symposium Merit Award Recipients! asco.org/quality/program/abs… #ASCOQLTY26 #CancerCare #CancerResearch @fumikochino @WhatsUrHari
4
15
7
49
5,913
Rural patients with lung cancer are now diagnosed at about the same stage as urban patients. They still die sooner, and the gap appears to be growing. That is my reading of Abstract 171 at this week's ASCO Quality Care Symposium: 1.19 million people with NSCLC, 2010–2023. The odds of early-stage diagnosis are now similar across rural and urban areas. What worsened is timeliness: the odds of starting treatment within 30 days fell to 0.88 for nonmetropolitan patients. A SEER-Medicare analysis (Abstract 209) shows the same pattern from another angle. One-year survival rose from 44% to 49% in urban counties between 2013–16 and 2017–21, but only from 45% to 47% in rural ones. Rural counties started level and fell behind during the years immunotherapy arrived. Three more findings on place and policy: • Oncologist supply grew by half in a decade, mostly where access was already good. (Abstract 80) • Federal housing assistance was associated with more guideline-concordant treatment and lower mortality. (Abstracts 177, 228) • Air quality tracked with survival after diagnosis in 1.67 million patients, though the estimate needs adjustment for smoking and income. (Abstract 697) My take: new treatments can widen disparities before they narrow them, because they reach well-resourced centers first. Stage at diagnosis looks similar across rural and urban areas in these data, but screening uptake is low everywhere, so detection is not solved. What these abstracts add is a delivery gap on top of it: rural patients now also wait longer for treatment. And 8.5% of rural counties outperform most urban ones, so it can be done. #ASCOQLTY26 #LungCancer #RuralHealth #HealthEquity
4
11
308
Lung cancer screening only works for the people it reaches. Seven abstracts at this week's Quality Care Symposium on who gets screened, who gets missed, and what closes the gap. One thread per abstract to follow. #ASCOQLTY26 #LCSM @ASCO
7
1
23
2,129
Thank you @JamesFanWu for highlighting our LCS program! Excellent thread! We're excited to share our results and some of the ways we've improved adherence to lung cancer screening at our safety-net hospital. 📍 Poster Session B | Abstract #155 📅 October 17 | 7:20–8:20 AM EDT
Abstract 155 at #ASCOQLTY26: can lung cancer screening work in a safety-net system? University of Illinois Health screened 3,872 people and reports 85% annual adherence. A short thread on what's in it and how I read it. @GarradEvan @MaryPasquinelli #lcsm 1/5 asco.org/abstracts-presentat…
2
2
209
Today, our @SclcSMASHERS received unfortunate news regarding infintamab deruxtecan (I-DXd). As you may recall, I-DXd is a B7-H3 directed antibody-drug conjugate (i.e., chemotherapy as a biological Trojan horse) that has been studied in SCLC. We have been anticipating the @FDA would complete their PDUFA process for accelerated approval of I-DXd by October 2026. Unfortunately, the company Merck (along with the Rx developer Daichii Sankyo) has WITHDRAWN their application from the FDA for accelerated approval today. The company expressed concerns that I-DXd may have not been approved with only Phase 2 study findings (IDEATE-LUNG-01, which were positive with high # of responses with brisk time to response) and the Phase 3 study (IDEATE-LUNG-02) is nearing completion. While I am hopeful that the Phase 3 data for I-DXd in the future, given two positive Phase 3 studies (Tam-Peli and Riz-Rez) at #WCLC26, this update makes it especially challenging, with lurbinectedin being revoked as well for patients who need options for relapsed SCLC, post tarlatamab. 🚨 I cannot emphasize enough that more clinical trials & agents in the space are vital, CLEAR unmet needs exist, and trials should be discussed with our patients at every major treatment decision in #SCLC to improve the care for every patient impacted by SCLC. @LUNGevity @lungoncdoc @StephenVLiu @alissajcooper @Sonampuri @BZhangMD @LaurenByersMD @BalazsHalmosMD @OncBrothers @OncoAlert @OncLive @YoungLungCancer @Lung_Cancers @RManochakian @Latinamd @TheShieldsLab @lcrf_org @LungCancerEu @oncodaily #lcsm
3
23
3
64
7,596
Highlights from #WCLC26 #CommunityOncology: NSCLC 1. #ADAURA Update Adj mEGFR 2. #PAPILLON 1L EGFR Ex20 3. #DESTINYLung04 1L mHER2 4. #ARROS1 1L ROS1+ 5. #HARMONi 2L mEGFR SCLC 6. #MAVERICK @SWOG MRI surv 7. #DeLLphi Tarla SubQ & ⬇️ freq #lcsm #OncTwitter @IASLC 1/8
2
48
4
101
11,691
#HARMONi …. Western follow up now out to ~23 months. Reassuring that the direction and magnitude of effect have converged with the global population as the data have matured. @IASLC #WCLC26
Replying to @OncBrothers
5. #HARMONi: 2L (after 3rd gen EGFRi), Ivonescimab (PD1/VEGF BsAb) + Chemo vs Chemo in EGFR+ mNSCLC: - mOS 16.8mos vs 14.0mos (HR: 0.79, p value: 0.057) - Ivonescimab starting to show positive data in more and more global studies. - Refractory mEGFR is a crowded space 6/8
8
2
19
8,869
#WCLC26 Presidential Symposium Day 2 #ADAURA: Adjuvant osimertinib — exploratory 8-year OS landmark update 🎙@DrRoyHerbst 🎯8-y OS 74% (osimertinib) vs 58% (placebo; HR 0.53); Stage IB-IIIA: 79% vs 64% (HR 0.52) 🎯Ex19del shows stronger OS benefit (HR 0.45) vs L858R (HR 0.72) 👉🏽remaining questions❓ -what is role of chemo -can we de-escalate treatment @iaslc @EGFRSummit @EGFRResisters
1
7
7
1,019
Phase II study of first-line QLC5508 (MHB088C, a B7-H3 ADC) with either QL1706 (PD1/CTLA4 bispecific) or QL2107 (pembro biosimilar) in ES-SCLC from #WCLC26. As with other recent studies, note ~30% of pts with no smoking history. RR for both regimens > 80% with DCR 100%. Toxicity primarily hematologic with <10% discontinuation. Encouraging - need data on durability, CNS efficacy, but another promising B7-H3 ADC for SCLC here!
3
15
1
35
6,487
Incredible time at my first #WCLC26, made even more special having my wife there as a patient advocate 😊 Grateful to be part of an amazing team at @UICancerCenter, to present our work on Sybil, and learn about exciting science to bring back to our patients🫁 Thank you Seoul! 🇰🇷
1
3
19
1,305
Evan Garrad retweeted
Could not agree more with Dr. Heuvelmans—an impressive AUC is not sufficient to implement healthcare #AI tools. We need prospectively-validated thresholds to determine how to actually use these models to improve patient outcomes. #lungcancerscreening #WCLC2026
1
3
194
Another ADC joins the SCLC armamentarium! Tam-Peli with huge OS, PFS and intracranial benefit over topotecan!! #WCLC26. Wonderful to have more options. Optimal choice of agent(s), sequencing, and resistance are areas of future investigation. @IASLC @SclcSMASHERS @drshieldsmd
1
10
38
1,302
Evan Garrad retweeted
Quick take from #WCLC26: Tam-Peli showed a clear overall survival advantage vs topotecan on the slide presented today: Median OS: 13.3 vs 9.4 months HR: 0.46 (95% CI 0.35–0.62) P < 0.0001 Reported as a 54% reduction in the rate of death Striking OS signal. More detailed thoughts soon. @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @latinamd @colazagasti @openmedicineHQ @asco @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @lungoncdoc @OncodailyLung @ClinicalLung #LCSM @LungPolicy #LungCancer #SCLC #ThoracicOncology
1
6
14
1,209
Really helpful session for early trainees preparing for a career in oncology. Great discussion on communication, using social media to help patients find their communities, and navigating conversations about misinformation. #WCLC26 @IASLC I’ll continue to use X for now tho 😬
7
1
15
921
Ready for Day 1 of @IASLC #WCLC26! 🇰🇷🫁 Looking forward to connecting with other advocates and hearing about new findings that could mean better options for patients like my dad. Grateful to @LUNGevity for their support and advice as I get more involved in lung cancer advocacy.
2
1
5
1,096
🫁 Ready for #WCLC26! 🇰🇷 I’ve put together a Notion database: 
📚 210 Plenary, Oral & Mini Oral presentations 📝 181 summaries of abstracts released so far
🏷️ Biomarker, stage & treatment tags scratch-work-2af.notion.site…
12
4
60
10,400